Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.34 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.34 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.33 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.33 |
| ▸ | DDB1 known ✓ | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN known ✓ | Q96SW2 | 1/20 | 0.32 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6414384 | 0.98 | TSHR (0.36) | TSHRALDH1A1SMN1; SMN2HSD17B10MAOB | |
| SCHEMBL44650 | 0.73 | SIGMAR1 (0.44) | TSHRALDH1A1SMN1; SMN2HSD17B10MAOB | |
| SCHEMBL20601589 | 0.72 | SLC18A3 (0.41) | TSHRHSD17B10MAOBKDM1AMAOA | |
| Hydrochloric Acid SCHEMBL8983182 | 0.66 | BLM (0.47) | TSHRALDH1A1SMN1; SMN2HSD17B10MAOB | |
| SCHEMBL15570404 | 0.66 | BRD4 (0.46) | TSHRHSD17B10MAOBKDM1AMAOA | |
| SCHEMBL9872211 | 0.65 | ALDH1A1 (0.38) | TSHRALDH1A1SMN1; SMN2HSD17B10MAOB | |
| SCHEMBL10109189 | 0.65 | SLC18A3 (0.35) | TSHRMAOBKDM1AMAOASLC18A3 | |
| SCHEMBL383636 | 0.64 | — | — | |
| SCHEMBL28529394 | 0.64 | — | — | |
| SCHEMBL2403745 | 0.64 | GAA (0.38) | TSHRALDH1A1SMN1; SMN2HSD17B10MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050191261-A1 | Process for strengthening hair and improving the compatibility of a treatment for waving the hair with another subsequent cosmetic treatment comprising applying derivatives of 2-iminothiolane | L'OREAL S.A. (FR) | 2005-09-01 | — | — | US | claimed |
| US-7053068-B2 | Chitosan-thio-amidine conjugates and their cosmetic as well as pharmaceutic use | MUCOBIOMER BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTWICKLUNGS GESMBH (AT) | 2006-05-30 | — | — | US | disclosed |
| US-20050191261-A1 | Process for strengthening hair and improving the compatibility of a treatment for waving the hair with another subsequent cosmetic treatment comprising applying derivatives of 2-iminothiolane | L'OREAL S.A. (FR) | 2005-09-01 | — | — | US | disclosed |
| US-20040236095-A1 | Chitosan-thio-amidine conjugates and their cosmetic as well as pharmeceutic use | MUCOBIOMER BIOTECHNOLOGISCHE FORSCHUNGS-UND ENTWICKLUNGS GESMBH (AT) | 2004-11-25 | — | — | US | disclosed |
| CN-1549829-A | Chitosan-thio-amidine conjugates and their cosmetic as well as pharmaceutic use | 穆考彼姆尔生物技术研究与发展有限公 | 2004-11-24 | — | — | CN | disclosed |
| EP-1456246-A1 | CHITOSAN-THIO-AMIDINE CONJUGATES AND THEIR COSMETIC AS WELL AS PHARMACEUTIC USE | Mucobiomer Biotechnologische Forschungs- und Entwicklungs GESMBH (AT) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003020771-A1 | CHITOSAN-THIO-AMIDINE CONJUGATES AND THEIR COSMETIC AS WELL AS PHARMACEUTIC USE | MUCOBIOMER BIOTECHNOLOGISCHE FORSCHUNGS- UND ENTWICKLUNGS GESMBH (AT) | 2003-03-13 | — | — | WO | disclosed |
| US-5183904-A | Hindered linking agents and methods | XOMA CORPORATION (US) | 1993-02-02 | — | — | US | disclosed |
| US-5093475-A | Immunotoxins | XOMA CORPORATION (US) | 1992-03-03 | — | — | US | disclosed |
| EP-0454726-A4 | HINDERED LINKING AGENTS AND METHODS | — | 1991-11-27 | — | — | EP | disclosed |
| EP-0454726-A1 | HINDERED LINKING AGENTS AND METHODS | Xoma Corporation (US) | 1991-11-06 | — | — | EP | disclosed |
| WO-1990006774-A1 | HINDERED LINKING AGENTS AND METHODS | XOMA CORPORATION (US) | 1990-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050191261-A1 | Process for strengthening hair and improving the compatibility of a treatment for waving the hair with another subsequent cosmetic treatment comprising applying derivatives of 2-iminothiolane | IWS1, WFS1, INMT | MAOB 369/4885MAOA 476/4885SIGMAR1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.